The global GLP-1 receptor agonist market, used primarily for type 2 diabetes and obesity management, is projected to grow from $28.7 billion in 2025 to $95.3 billion by 2035, at a compound annual growth rate of 12.1%. Growth is fueled by rising diabetes and obesity cases worldwide, innovations in drug formulations including oral options, and expanded healthcare access. North America leads the market, while Asia Pacific shows the fastest growth due to increasing patient numbers and healthcare improvements. Key players include Novo Nordisk, Eli Lilly, and Sanofi, with ongoing advancements like Eli Lilly's oral GLP-1 showing promising clinical results.
Novo Nordisk has regained investor confidence driven by strong demand for its Wegovy weight loss pill, which is helping stabilize its market share. While the company expects a 7% sales decline in 2024 due to U.S. pricing pressures, its international ...
Novo Nordisk reported a decline in adjusted sales and operating profit for Q1 2026, yet its obesity care segment, particularly the Wegovy pill, showed strong growth and outperformed competitors like Eli Lilly. The company benefits from patent protect...
At the American Diabetes Association conference, leading drugmakers like Eli Lilly and Novo Nordisk showcased new obesity treatments including advanced GLP-1 pills and shots promising greater weight loss and easier dosing schedules. Eli Lilly's exper...
